Showing 2461-2470 of 3039 results for "".
- Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meetinghttps://modernod.com/news/glaukos-technologies-featured-in-numerous-scientific-abstracts-at-the-2022-american-academy-of-ophthalmology-annual-meeting/2481136/Glaukos announced that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held September 30-October 3, 2022 in Chicago. Key Glaucoma Presentations: Bryan CH Ang, MD Novel
- Tarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitishttps://modernod.com/news/tarsus-launches-look-at-the-lids-campaign-to-encourage-eye-care-professionals-to-identify-and-diagnose-demodex-blepharitis/2481133/Tarsus Pharmaceuticals announced the launch of the “Look at the Lids” disease education campaign for Demodex blepharitis, a common lid margin disease that can negatively impact patients’ daily activities and eyelid health. The novel campaign is designed to encourage ey
- Johnson & Johnson Vision Expands Access to Myopia Management for More Patients With Abiliti Overnight Lenseshttps://modernod.com/news/johnson-johnson-vision-expands-access-to-myopia-management-for-more-patients-with-abiliti-overnight-lenses/2481127/Johnson & Johnson Vision announced FDA approval of an expanded range of ACUVUE Abiliti Overnight Therapeutic Lenses for Myopia Management, now up to 6.00 diopters (previously 4.00 diopters). Johnson & Johnson Vision also announced greater availability of the lenses nationwi
- Alimera Announces Reimbursement of Uveitis Indication Granted for Iluvien in Irelandhttps://modernod.com/news/alimera-announces-reimbursement-of-uveitis-indication-granted-for-iluvien-in-ireland/2481105/Alimera Sciences announced that Alimera Sciences Europe, its Ireland-based European subsidiary, has been granted reimbursement for Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for noninfectious uveitis affecting the posterior segme
- Trukera Medical Launches ScoutPro Osmolarity Systemhttps://modernod.com/news/trukera-medical-launches-new-scoutpro-osmolarity-system/2481081/Trukera Medical unveiled the first product under the new company name, the ScoutPro Osmolarity System. Designed to help advance corneal health decisions for busy eye care practices, ScoutPro is the first and only portable osmometer in the United States. The launch comes a wee
- Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and Wet AMD for 12- and 16-Week Dosinghttps://modernod.com/news/aflibercept-8-mg-meets-primary-endpoints-in-two-global-pivotal-trials-for-dme-and-wet-amd-for-12-and-16-week-dosing/2481071/Regeneron Pharmaceuticals announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The PHOTON trial in DME and the PUL
- SamaCare’s Prior Authorization Management Platform Available on the ModMed EMRhttps://modernod.com/news/samacares-prior-authorization-management-platform-available-on-the-modmed-emr/2481065/Retina and multi-specialty ophthalmology practices will now be able to synchronize data and share documents between the ModMed all-in-one ophthalmology solution and SamaCare’s prior authorization management platform, according to a SamaCare news release. The interface su
- Glaukos Announces More Than 1 Million iStent Devices Implanted Worldwidehttps://modernod.com/news/glaukos-announces-more-than-1-million-istent-devices-implanted-worldwide/2481064/Glaukos announced that it has reached a milestone with its iStent family of technologies having now been implanted in more than 1 million procedures worldwide. “One million iStents implanted is a tremendous accomplishment and I’m grate
- Iveric Bio Announces Positive Topline Data from Zimura GATHER2 Phase 3 Clinical Trial in Geographic Atrophyhttps://modernod.com/news/iveric-bio-announces-positive-topline-data-from-zimura-gather2-phase-3-clinical-trial-in-geographic-atrophy/2481062/Iveric bio announced positive topline results from GATHER2, the company’s second phase 3 clinical trial of Zimura (avacincaptad pegol), a novel investigational complement C5 inhibitor, for the treatment of geographic atrophy (GA). GATHER2 met its prespecified primary endpoint of mean r
- iTrack Canaloplasty to be Featured at the 2022 ESCRS Annual Meetinghttps://modernod.com/news/itrack-canaloplasty-to-be-featured-at-the-2022-escrs-annual-meeting/2481051/Nova Eye Medical announced that the company’s proprietary canaloplasty technology platform (iTrack™ and iTrack™ Advance) will be featured during the official scientific program of the European Society of Cataract and Refractive Surgeons (ESCRS) 40th Congress on Septemb